pdufa.bio

ZENBEXUS (iberdomide)

Updated ยทnext FDA decision on the calendar

ZENBEXUS (iberdomide) 1 FDA decision on record below. Every date links its source.

BMY catalyst hub

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Aug 13, 2026 ✓ ApprovedBMY

Questions

When is ZENBEXUS (iberdomide)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for ZENBEXUS (iberdomide); 1 FDA decision is on record below.

What happened at ZENBEXUS (iberdomide)'s most recent FDA decision?

On Aug 13, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has ZENBEXUS (iberdomide) been approved by the FDA?

Yes. The FDA approved an application for ZENBEXUS (iberdomide) on Aug 13, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.